Jake Simson - 10 Jun 2021 Form 4 Insider Report for Janux Therapeutics, Inc. (JANX)

Reporting relationship: Director
Issuer ticker: JANX
Reported as of: 10 Jun 2021
Net transaction value: $0
SEC form: 4
Accepted by SEC: 14 Jun 2021, 17:40:25 UTC
Next SEC filing: 14 Sep 2021
Source filing: View source filing
Reporting owner signature: /s/ Tighe Reardon, Attorney-in-Fact

Key filing fact

Jake Simson filed Form 4 for Janux Therapeutics, Inc. (JANX) on 14 Jun 2021.

Key facts

This page summarizes Jake Simson's Form 4 filing for Janux Therapeutics, Inc. (JANX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 14 Jun 2021, 17:40.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

JANX transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +30,000
Change %
Price: $0.000000
Shares after: 30,000
Date: 10 Jun 2021
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 30,000
Exercise price: $17.00
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The shares subject to the option will vest in equal monthly installments over the 36 months following June 10, 2021.

Footnote F2

Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the option for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received from the option, which will offset advisory fees owed by the Fund and the Nexus Fund II to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock.